Rayburn W F
Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha 68105.
Am J Obstet Gynecol. 1989 Mar;160(3):529-34. doi: 10.1016/s0002-9378(89)80020-1.
This report summarizes the cumulative experience of 3313 pregnancies represented in 59 prospective clinical trials in which intracervical or intravaginal prostaglandin E2 gel was used for cervical ripening before induction of labor. Results indicate that local prostaglandin E2 is superior to placebo or no therapy in enhancing cervical effacement and dilation, reducing initial induction failures, shortening the induction-delivery interval, reducing oxytocin use, and lowering the rate of cesarean section because of failure to progress. Certain advantages also exist for labor induction in the presence of a favorable cervical state. Uterine hyperstimulation or pathologic fetal heart rate patterns before oxytocin administration occur in less than 1% of reported cases and are usually dose related, self contained, and reversible with the use of beta-adrenergic tocolytic therapy. Maternal systemic effects in these low doses are negligible. Worldwide clinical experience has clearly demonstrated that prostaglandin E2 gel administered before induction of labor is of major therapeutic benefit and should become commercially available for more than investigational use.
本报告总结了59项前瞻性临床试验中3313例妊娠的累积经验,这些试验使用宫颈内或阴道内前列腺素E2凝胶在引产前行宫颈成熟。结果表明,局部使用前列腺素E2在促进宫颈消退和扩张、减少初始引产失败、缩短引产至分娩间隔、减少催产素使用以及降低因产程无进展而行剖宫产的比率方面优于安慰剂或不治疗。在宫颈条件良好的情况下引产也有某些优势。催产素给药前子宫过度刺激或病理性胎心率模式在报告病例中不到1%,通常与剂量相关,自行缓解,使用β-肾上腺素能宫缩抑制剂治疗可逆转。这些低剂量对母体的全身影响可忽略不计。全球临床经验已清楚表明,引产前行前列腺素E2凝胶给药具有重大治疗益处,应可供商业使用而非仅用于研究。